SCHEMBL22290686

SCHEMBL22290686

Brc1cccc(-c2cnn(C3CC3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.43
METAP2 P50579 1/20 0.43
HCRTR1 O43613 2/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
HK1 P19367 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
GABRA1 P14867 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290460 0.76 LIPG (0.38) HCRTR1
SCHEMBL2658449 0.74 IDO1 (0.47) IDO1METAP2HCRTR1RAB9ANPC1
SCHEMBL29009128 0.74 HCRTR1 (0.45) HCRTR1RAB9ANPC1ALDH1A1HPGD
SCHEMBL22290867 0.71 IDO1 (0.44) IDO1METAP2HCRTR1RAB9ANPC1
SCHEMBL20899866 0.70 HCRTR1 (0.39) HCRTR1SMN1; SMN2LMNAPDE4D
SCHEMBL3843814 0.68 SMN1; SMN2 (0.40) IDO1METAP2HCRTR1RAB9ANPC1
SCHEMBL20899673 0.68 HCRTR1 (0.38) HCRTR1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL17027901 0.67 IDO1 (0.58) IDO1METAP2RAB9ANPC1MAPT
SCHEMBL20899947 0.67
SCHEMBL28278292 0.65 GABRA1 (0.45) IDO1METAP2HCRTR1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 CN disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB IDO1 4864/4885METAP2 3240/4885HCRTR1 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.